Docetaxel in combination with octreotide shows synergistic apoptotic effect by increasing SSTR2 and SSTR5 expression levels in prostate and breast cancer cell lines

Simple item page
dc.contributor.authorKaraca B.
dc.contributor.authorDegirmenci M.
dc.contributor.authorOzveren A.
dc.contributor.authorAtmaca H.
dc.contributor.authorBozkurt E.
dc.contributor.authorKarabulut B.
dc.contributor.authorSanli U.A.
dc.contributor.authorUslu R.
dc.date.accessioned2024-07-22T08:13:14Z
dc.date.available2024-07-22T08:13:14Z
dc.date.issued2015
dc.description.abstractPurpose: Docetaxel (DTX) is widely used for the treatment of metastatic prostate and breast cancers. Despite the clinical success of DTX, drug-related cumulative toxicity restricts its clinical use in cancer therapy. Thus, there is an urgent need for new therapeutic options. Octreotide (OCT) is a synthetic somatostatin analog that induces apoptosis in different cancer cell lines in vitro. In this study, we investigated the possible synergistic apoptotic effects of DTX in combination with OCT in prostate and breast cancer cell lines. Methods: The XTT cell viability assay was used to determine cytotoxicity. Apoptosis was evaluated by Cell Death Detection ELISAPlus Kit. The expression levels of apoptotic proteins were assessed by human apoptosis antibody array. Levels of SSTR2 and SSTR5 proteins were determined by western blot analysis. Results: DTX and OCT combination induced apoptosis in both breast and prostate cancer cells in a concentration- and time-dependent manner. Moreover, combination treatment resulted in inhibition of anti-apoptotic proteins such as Bcl-2 and Bcl-xL and induction of pro-apoptotic proteins Bax, Cytochrome c and IAPs in all of the tested cancer cell lines. SSTR2 and SSTR5 protein levels were induced as compared to any agent alone. Conclusions: These results indicate that this combination treatment is a significant inducer of apoptosis in a synergistic manner in breast and prostate cancer cells. This strong synergism helps to lower the dose of DTX in both types of cancers, thus letting DTX to be used for longer periods by delaying resistance development and lesser side effects. © 2015 Springer-Verlag Berlin Heidelberg.
dc.identifier.DOI-ID10.1007/s00280-015-2756-1
dc.identifier.issn03445704
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/16303
dc.language.isoEnglish
dc.publisherSpringer Verlag
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectApoptosis
dc.subjectApoptosis Regulatory Proteins
dc.subjectbcl-2-Associated X Protein
dc.subjectbcl-X Protein
dc.subjectBreast Neoplasms
dc.subjectCell Line, Tumor
dc.subjectCell Survival
dc.subjectCytochromes c
dc.subjectDrug Synergism
dc.subjectFemale
dc.subjectHumans
dc.subjectInhibitor of Apoptosis Proteins
dc.subjectMale
dc.subjectOctreotide
dc.subjectProstatic Neoplasms
dc.subjectProto-Oncogene Proteins c-bcl-2
dc.subjectReceptors, Somatostatin
dc.subjectTaxoids
dc.subjectcytochrome c
dc.subjectdocetaxel
dc.subjectoctreotide
dc.subjectprotein Bax
dc.subjectprotein bcl 2
dc.subjectprotein bcl xl
dc.subjectsomatostatin receptor 2
dc.subjectsomatostatin receptor 5
dc.subjectantineoplastic agent
dc.subjectapoptosis regulatory protein
dc.subjectBAX protein, human
dc.subjectBCL2L1 protein, human
dc.subjectcytochrome c
dc.subjectdocetaxel
dc.subjectinhibitor of apoptosis protein
dc.subjectoctreotide
dc.subjectprotein Bax
dc.subjectprotein bcl 2
dc.subjectprotein bcl x
dc.subjectsomatostatin receptor
dc.subjectsomatostatin receptor 5
dc.subjectsomatostatin receptor subtype 2, human
dc.subjecttaxoid
dc.subjectapoptosis
dc.subjectArticle
dc.subjectbreast cancer cell line
dc.subjectcell death
dc.subjectcell proliferation
dc.subjectcell viability assay
dc.subjectcontrolled study
dc.subjectcytotoxicity
dc.subjectDNA fragmentation
dc.subjectenzyme linked immunosorbent assay
dc.subjecthuman
dc.subjecthuman cell
dc.subjectmale
dc.subjectpriority journal
dc.subjectprostate cancer cell line
dc.subjectprotein expression
dc.subjectapoptosis
dc.subjectBreast Neoplasms
dc.subjectcell survival
dc.subjectdrug effects
dc.subjectdrug potentiation
dc.subjectfemale
dc.subjectgenetics
dc.subjectProstatic Neoplasms
dc.subjecttumor cell line
dc.titleDocetaxel in combination with octreotide shows synergistic apoptotic effect by increasing SSTR2 and SSTR5 expression levels in prostate and breast cancer cell lines
dc.typeArticle

Files

Collections

Scopus Koleksiyonu